Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting In a second oral presentation, results from a sub-group analysis of the primary study were ...
The U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) as a preventative measure against potential pulmonary ...
PRINCETON, N.J. & NEW YORK, Jun 27, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY -0.74% and Pfizer Inc. PFE -0.14% today announced that the Committee for Medicinal Products for Human Use ...
European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE In the AMPLIFY trial, Eliquis was ...
Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...
With the recent approval of apixaban in most major countries for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), all 3 of the new oral ...
U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients
U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus Warfarin ...
The novel oral anticoagulant apixaban has similar effects on stroke, systemic embolism and major bleeding in patients with atrial fibrillation (A-fib) whether they have been on previous warfarin ...
New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that with
New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon Results ...
Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and ...
New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that with
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and Pfizer Inc. (NYS: PFE) today announced results of a post-hoc subanalysis from the Phase III ARISTOTLE trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback